{"filing":{"accession_number":"0001213900-26-103735","cik":"0001723069","ticker":"TLSA","company_name":"Tiziana Life Sciences Ltd","form":"6-K","filing_date":"2026-09-28","report_date":"2026-09-28","primary_document":"ea0306829-6k_tiziana.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1723069/000121390026103735/ea0306829-6k_tiziana.htm"},"events":[{"id":35279,"run_id":32491,"accession_number":"0001213900-26-103735","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces a material clinical development milestone: the first participants dosed in the Phase 2a BANYAN clinical trial of intranasal foralumab for ALS. The disclosure describes trial design, enrollment criteria, endpoints, and investigator details. This represents a significant operational and strategic advancement for Tiziana's lead development candidate, affecting investor assessment of pipeline progress and clinical execution capability. While not a discrete event type like M\u0026A or exec change, it is clearly material operational progress in drug development.","company_name":"Tiziana Life Sciences Ltd","ticker":"TLSA","filing_date":"2026-09-28","form":"6-K","submitted_at":null,"items":[{"id":39279,"accession_number":"0001213900-26-103735","item_number":"EX-99.1","item_title":"ea030682901ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a material clinical development milestone: the first participants dosed in the Phase 2a BANYAN clinical trial of intranasal foralumab for ALS. The disclosure describes trial design, enrollment criteria, endpoints, and investigator details. This represents a significant operational and strategic advancement for Tiziana's lead development candidate, affecting investor assessment of pipeline progress and clinical execution capability. While not a discrete event type like M\u0026A or exec change, it is clearly material operational progress in drug development.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-28T11:09:53.984954+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39279,"accession_number":"0001213900-26-103735","item_number":"EX-99.1","item_title":"ea030682901ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a material clinical development milestone: the first participants dosed in the Phase 2a BANYAN clinical trial of intranasal foralumab for ALS. The disclosure describes trial design, enrollment criteria, endpoints, and investigator details. This represents a significant operational and strategic advancement for Tiziana's lead development candidate, affecting investor assessment of pipeline progress and clinical execution capability. While not a discrete event type like M\u0026A or exec change, it is clearly material operational progress in drug development.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-28T11:09:53.984954+00:00","company_name":"Tiziana Life Sciences Ltd","ticker":"TLSA","filing_date":"2026-09-28"}]}